Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

Toni K. Choueiri, MD
Published: Thursday, Oct 20, 2016



Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma (RCC).

Choueiri highlights one trial that is comparing a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) with sunitinib (Sutent) in patients with previously untreated metastatic RCC. Another trial is currently examining the efficacy of atezolizumab in combination with bevacizumab (Avastin) compared with sunitinib.

The takeaway message, according to Choueiri, is that the standard of care is constantly evolving. Clearly, the field is moving generally in the direction of combination treatments to treat patients with RCC.


Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma (RCC).

Choueiri highlights one trial that is comparing a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) with sunitinib (Sutent) in patients with previously untreated metastatic RCC. Another trial is currently examining the efficacy of atezolizumab in combination with bevacizumab (Avastin) compared with sunitinib.

The takeaway message, according to Choueiri, is that the standard of care is constantly evolving. Clearly, the field is moving generally in the direction of combination treatments to treat patients with RCC.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x